If the AI trade unwinds, other pillars holding up the U.S. economy are 'irrelevant,' says Barclays

By Nora Redmond

Barclays said it's targeting 8,700 for the S&P 500 in 2027.

If the artificial-intelligence trade really is unwinding, the other pillars holding up the U.S. economy are "irrelevant," according to strategists at Barclays.

For much of the past year, both the U.S. - and to a considerable degree, the global economy - have been supported by three pillars: the strength of the U.S. consumer, the durability of companies' financial results and the resilience of AI capital expenditure, the British bank highlighted in its outlook for the year ahead.

The first two have stayed standing, said Ajay Rajadhyaksha, global chairman of research. U.S. consumption has contributed 1.8% to gross domestic product growth this year, with the economy growing 2.7% in the first three quarters and expected to expand 3.2% in the final quarter, according to the Federal Reserve Bank of Atlanta's GDPNow tool.

For corporate earnings, about 84% of S&P 500 names have beaten analysts' estimates so far in the third quarter, bringing blended growth to 31% year-on-year. Wall Street consensus is for earnings growth of 15% in 2027, which if realized, will make the 2025 to 2027 period the strongest three-year period for earnings in a number of decades, he said.

"But all of that is irrelevant if the AI trade is truly unraveling," the strategist warned, noting that the tool has added more than one point to U.S. economic growth this year -and even that figure underestimates its influence as AI has affected virtually every sector.

Rajadhyaksha wrote: "The vast majority of trillion-dollar companies globally are AI-sensitive names. If the AI trade collapses, equity valuations will follow. Wealth effects will turn negative. The mighty U.S. consumer could finally wobble. The dominoes falling would extend far beyond technology."

Barclays forecasts the S&P 500 SPX to reach 8,700 in 2027, a target in line with Goldman Sachs and Morgan Stanley's.

That said, Barclays doesn't see the beginning stages of a collapse in the AI trade, instead arguing there's a correction, with investors rotating into cyclical, healthcare and defence stocks.

Despite a prolonged war in Iran, significant spikes in oil prices (CL00), turmoil in the French bond market BX:TMBMKFR-10Y and the sharpest selloff in AI stocks since the cycle first kicked off, global growth has managed to prevail, Rajadhyaksha and a team of strategists wrote in a separate note. The bank is targeting a 3.4% year-on-year global growth rate and a 2.4% expansion for the U.S.

For Rajadhyaksha, the overbuilding of AI will eventually become a problem - but not in 2027.

"A years-long bull market is unlikely to die when the leading semiconductor names have already de-rated sharply and trade at three to four times forward earnings - priced like distressed cyclicals," he said. "That is what mid-cycle fear looks like, not a bubble about to pop."

The PHLX semiconductor index SOX has dropped 34% from its June peak.

And on the Democrats' sweep of the midterm elections, the strategist wrote that some delays to the construction of data centers may actually benefit technology companies by minimizing the risk of overbuilding.

For the year ahead, Barclays is overweight equities over bonds and advises selectively buying into the AI correction.

Rajadhyaksha and the team of strategists recommend increasing exposure to established hyperscalers, profitable semiconductor names and companies that have proved monetization from AI and have the balance sheets to fund its development internally.

"We would be more cautious on businesses whose valuations depend on uninterrupted access to external capital, distant free cash flow or data center projects that have yet to secure power and permits," the strategists said.

They recommend value, quality and healthcare names as preferred hedges in the U.S. and European equities for those still skeptical about AI. But the bank also said all investors should broaden their exposure beyond just tech, maintaining a core allocation to the sector, while also buying more healthcare XLV, industrial XLIand high-quality growth stocks.

-Nora Redmond

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

11-19-26 0745ET

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center